Clinical trials: PDA, active
Patent Ductus Arterioses
Impact of Transcatheter Patent Ductus Arteriosus Closure on Left Atrial and Ventricular Remodeling in Adults and Adolescents.
During the fetal life, small portion of the RV output passes to the lung through the pulmonary artery, while the greater portion is shunted to the descending aorta through the fetal ductus arteriosus (1) which is a connection…
- Trial name
- NCT07568002
- Testing
- Transcatheter Patent Ductus Arteriosus Closure
- Volunteers
- 40 people
- Sponsor
- Emil Magdy Badry
Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity
Long Term Follow-up of the TREOCAPA Study (TREOCAPA-LT)
The ductus arteriosus (DA) is a large channel connecting the main pulmonary trunk with the descending aorta. In extremely preterm infants, the DA frequently fails to close and this results in a condition called patent ductus…
- Trial name
- TREOCAPA-LT (NCT06064825)
- Testing
- 2 year follow-up of neurodevelopment using a parental questionnaire
- Where
- 8 sites in France
- Volunteers
- 500 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Perinatal Depression, PerinatalAnxiety
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.
- Trial name
- NCT06074250
- Testing
- Fish oil, Probiotics, Prebiotics
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Patent Ductus Arteriosus
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects…
- Trial name
- NCT05264753
- Testing
- Occlutech® PDA Occluder
- Where
- 15 sites in Canada, France and 7 more
- Volunteers
- 255 people
- Sponsor
- Occlutech International AB
Shock, Preterm Birth Complication
Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial
The goal of this clinical trial is to determine the effectiveness of early use of hydrocortisone (since the diagnosis of shock) for its resolution within the first 72 hours in premature infants under 1,500 g.
- Conditions
- Shock, Preterm Birth Complication, Preterm Intraventricular Hemorrhage, Asphyxia Perinatal
- Trial name
- NCT07248761
- Testing
- Intravascular Hydrocortisone (stress dosage): 1 mg/k/dose each 8 hours for 5 days, Vasoactive drug therapies
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System.
- Trial name
- NCT07114718
- Testing
- Ductus Arteriosus Stent
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Starlight Cardiovascular Inc
Patent Ductus Arteriosus After Premature Birth
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
Patent ductus arteriosus (PDA), the most common cardiovascular complication of prematurity, is associated with higher mortality and morbidities in extremely low gestational age neonates (ELGANs, < 27+0 weeks).
- Trial name
- NCT05340582
- Testing
- Acetaminophen Injection, Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen), Sodium chloride 0.9% injection
- Where
- 9 sites in Australia, Canada and 2 more
- Volunteers
- 310 people
- Sponsor
- Mount Sinai Hospital, Canada
Patent Ductus Arteriosus, Preterm
Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even…
- Trial name
- MIPD-PDA (NCT07143201)
- Testing
- Standard Dose - Ibuprofen oral suspension, Precision Dose - Ibuprofen oral suspension
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Hamilton Health Sciences Corporation
Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with pancreatic ductal adenocarcinoma (PDA) that has…
- Conditions
- Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8
- Trial name
- NCT05518903
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
- Trial name
- NCT05093231
- Testing
- Pembrolizumab, Olaparib
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Left Ventricular Hypertrophy
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Hypothesis/Study question In infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure/performance and lung water content? Study objectives To measure effects…
- Trial name
- SPEC (NCT04644094)
- Testing
- Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Ductus Arteriosus, Patent
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth.
- Trial name
- PIVOTAL (NCT05547165)
- Testing
- Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
- Where
- 24 sites in United States
- Volunteers
- 240 people
- Sponsor
- Nationwide Children's Hospital
Coarctation of the Aorta, Aortic Arch Obstruction
The Arch Watch Study: An Integrated Evaluation of Hemodynamics in Infants With Suspected Coarctation of the Aorta
Unrecognized coarctation of the aorta (CoA) is a life-threatening component of congenital heart disease (CHD) in which narrowing of the aorta causes obstructed blood flow to the lower half of the body; it can occur in isolation…
- Trial name
- NCT05880576
- Testing
- Monitoring using resonance Raman spectroscopy, pulse oximetry, blood pressure, and near-infrared spectroscopy
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular…
- Trial name
- SuMILE (NCT07356778)
- Testing
- Sotatercept, vasodilator-based PAH therapy
- Where
- 10 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Kazuya Hosokawa
Hemodynamically Significant Patent Ductus Arteriosus
Research on the Individualized Treatment Strategy for Extremely Preterm Infants With hsPDA Based on Biomarkers and Targeted Delivery Systems
This project aims to address the need for individualized precision therapy for hemodynamically significant patent ductus arteriosus (hsPDA) in extremely preterm infants by integrating clinical biomarker screening with the design…
- Trial name
- BTDS-IT-hsPDA- (NCT07374146)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Patent Ductus Arteriosus, Preterm Infant
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
Patent ductus arteriosus (PDA), very common in preterm infants, is the delayed closure of a fetal blood vessel that limits blood flow through the lungs.
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia, Neurodevelopmental Abnormality
- Trial name
- NCT03782610
- Where
- 4 sites in United States
- Volunteers
- 526 people
- Sponsor
- Nationwide Children's Hospital
Preterm, Patent Ductus Arteriosus
NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot
Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates.
- Conditions
- Preterm, Patent Ductus Arteriosus, Sepsis, Asphyxia
- Trial name
- CE-NeoDoppler (NCT06646250)
- Testing
- NeoDoppler - CE certified
- Where
- Norway
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- St. Olavs Hospital
Patent Ductus Arteriosus in Preterm Infants
Radiological Markers for PDA Management in Preterm Infants
The aim of this Randomized controlled trial is to determine whether Echo with Organ Doppler-guided management strategy for hemodynamically significant patent ductus arteriosus (hsPDA) improves the short-term outcomes compared…
- Trial name
- NCT07812064
- Testing
- Organ doppler, Echocardiography
- Volunteers
- 88 people
- Sponsor
- Assiut University
Ductus Arteriosus, Patent
The U.S. PDA Registry
The objective of this study is to demonstrate the continued safety and efficacy in a real-world setting of transcatheter device closure of the PDA in premature infants less than 2kg in weight at the time of device implant using…
- Trial name
- NCT04205877
- Testing
- Transcatheter PDA Closure
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Le Bonheur Children's Hospital
Preterm, Ductus Arteriosus
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
The ductus arteriosus quickly closes itself. is an important channel connecting the maternal fetal circulation before birth. After birth, this ductus arteriosus generally no longer has a physical function, so ductus arteriosus…
- Trial name
- PDA (NCT06950164)
- Testing
- observation group, control group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University